论文部分内容阅读
目的探讨肿瘤转移抑制基因(nm23-H1)在晚期食管癌中表达与化疗敏感性的关系。方法应用免疫组化分析方法,检测57例食管癌患者nm23-H1表达,以铂类为主化疗至少2个疗程后进行化疗效果评价。结果nm23-H1阳性率为42.1%,与食管癌的临床组织分级有关,而与淋巴结转移、性别、年龄、位置及细胞分化无关;nm23-H1(+)的患者,其化疗敏感性明显优于nm23-H1(-)患者。结论晚期食管癌患者中,恶性度越高,nm23-H1表达越高。nm23-H1提示术后以铂类药物为主的化疗敏感性。
Objective To investigate the relationship between the expression of nm23-H1 gene and the chemosensitivity in advanced esophageal cancer. Methods Immunohistochemical method was used to detect the expression of nm23-H1 in 57 patients with esophageal cancer. Chemotherapy was evaluated after at least 2 cycles of platinum-based chemotherapy. Results The positive rate of nm23-H1 was 42.1%, which was correlated with the clinical grade of esophageal cancer, but not with lymph node metastasis, sex, age, location and cell differentiation. The sensitivity of nm23-H1 (+) was significantly better than that of nm23- nm23-H1 (-) patients. Conclusion In patients with advanced esophageal cancer, the higher the degree of malignancy, the higher the expression of nm23-H1. nm23-H1 prompted postoperative platinum-based chemosensitivity.